Ashley Ware, OD
Optometrist · Montgomery, ALNPI 1386907970
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,021 of the $8,915 with a category attached, or 90.0%. 22 manufacturers reported payments, led by Alcon at 32.0% of the total. Reporting peaked in 2019 at $2,574 and has fallen 67.1% since, to $846 in 2025. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Kala Pharmaceuticals, Inc.$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$961
- Bausch & Lomb Americas Inc.$548
- Bausch & Lomb, A Division Of Bausch Health US, LLC$437
- plus $897 from 16 others
What the payments were for
- Travel & lodging$87610%
- Food & beverage$8,02190%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 82 | $2,853 |
| Kala Pharmaceuticals, Inc. | 15 | $1,889 |
| AbbVie(2 entities) | 64 | $1,331 |
| Sun Pharmaceutical Industries Inc. | 34 | $961 |
| Bausch & Lomb Americas Inc. | 16 | $548 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $437 |
| Novartis | 11 | $174 |
| Glaukos Corporation | 1 | $149 |
| Harrow Eye, LLC | 3 | $78 |
| Oyster Point Pharma, Inc. | 4 | $77 |
| Biotissue Holdings Inc. | 3 | $66 |
| Aerie Pharmaceuticals, Inc. | 3 | $52 |
| Dompe US, Inc. | 2 | $49 |
| Akorn, Inc. | 2 | $41 |
| Thea Pharma Inc. | 2 | $39 |
| Rxsight Inc | 2 | $35 |
| Heidelberg Engineering, Inc. | 1 | $27 |
| Sight Sciences, Inc. | 1 | $25 |
| Akorn Operating Company LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $22 |
| Alcon Research LLC | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,915 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $100,837 |
| LumiganBimatoprost | 81 | $36,443 |
| XiidraLifitegrast | 24 | $35,921 |
| Cyclosporine | 41 | $32,764 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 145 | $31,254 |
| CequaCyclosporine | 13 | $17,627 |
| Latanoprost | 703 | $17,227 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $13,482 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 274 | $4,880 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,548 |
| Timolol Maleate | 181 | $2,679 |
| Prednisolone Acetate | 63 | $2,410 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 44 | $2,079 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $2,043 |
| Brimonidine Tartrate | 96 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,331 | $150,762200 claims |
| Bausch & Lomb Americas Inc.Xiidra | $548 | $35,92124 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $961 | $17,62713 claims |
| AlconSimbrinza | $2,853 | $3,54816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Montgomery
- April HillMontgomery$7K
- Michael MullMontgomery$7K
- Tyler McFadenMontgomery$6K
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
- Benjamin KachelmanFlorence$101K
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Jack SchaefferHoover$60K
- Leo SemesBirmingham$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.